APYX MEDICAL CORP (APYX) Stock Fundamental Analysis

NASDAQ:APYX • US03837C1062

3.42 USD
-0.12 (-3.39%)
Last: Feb 25, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, APYX scores 2 out of 10 in our fundamental rating. APYX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. APYX may be in some trouble as it scores bad on both profitability and health. APYX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • APYX had negative earnings in the past year.
  • APYX had a negative operating cash flow in the past year.
  • APYX had negative earnings in each of the past 5 years.
  • In the past 5 years APYX always reported negative operating cash flow.
APYX Yearly Net Income VS EBIT VS OCF VS FCFAPYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

  • The Return On Assets of APYX (-25.35%) is comparable to the rest of the industry.
  • The Return On Equity of APYX (-248.63%) is worse than 74.59% of its industry peers.
Industry RankSector Rank
ROA -25.35%
ROE -248.63%
ROIC N/A
ROA(3y)-34.86%
ROA(5y)-28.54%
ROE(3y)-98.96%
ROE(5y)-68.76%
ROIC(3y)N/A
ROIC(5y)N/A
APYX Yearly ROA, ROE, ROICAPYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

  • Looking at the Gross Margin, with a value of 62.65%, APYX is in the better half of the industry, outperforming 66.49% of the companies in the same industry.
  • In the last couple of years the Gross Margin of APYX has declined.
  • The Profit Margin and Operating Margin are not available for APYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.12%
GM growth 5Y-2.02%
APYX Yearly Profit, Operating, Gross MarginsAPYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • APYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • APYX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for APYX has been increased compared to 5 years ago.
  • APYX has a worse debt/assets ratio than last year.
APYX Yearly Shares OutstandingAPYX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
APYX Yearly Total Debt VS Total AssetsAPYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of 0.63, we must say that APYX is in the distress zone and has some risk of bankruptcy.
  • APYX has a Altman-Z score (0.63) which is in line with its industry peers.
  • A Debt/Equity ratio of 5.92 is on the high side and indicates that APYX has dependencies on debt financing.
  • With a Debt to Equity ratio value of 5.92, APYX is not doing good in the industry: 85.41% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 5.92
Debt/FCF N/A
Altman-Z 0.63
ROIC/WACCN/A
WACC11.02%
APYX Yearly LT Debt VS Equity VS FCFAPYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • APYX has a Current Ratio of 4.44. This indicates that APYX is financially healthy and has no problem in meeting its short term obligations.
  • APYX has a better Current ratio (4.44) than 72.97% of its industry peers.
  • A Quick Ratio of 3.61 indicates that APYX has no problem at all paying its short term obligations.
  • APYX has a better Quick ratio (3.61) than 71.35% of its industry peers.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 3.61
APYX Yearly Current Assets VS Current LiabilitesAPYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 56.63% over the past year.
  • The Revenue has decreased by -1.32% in the past year.
  • The Revenue has been growing by 11.24% on average over the past years. This is quite good.
EPS 1Y (TTM)56.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.29%
Revenue 1Y (TTM)-1.32%
Revenue growth 3Y-0.29%
Revenue growth 5Y11.24%
Sales Q2Q%12.1%

3.2 Future

  • Based on estimates for the next years, APYX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.24% on average per year.
  • The Revenue is expected to grow by 41.40% on average over the next years. This is a very strong growth
EPS Next Y52.43%
EPS Next 2Y20.18%
EPS Next 3Y14.41%
EPS Next 5Y18.24%
Revenue Next Year9.08%
Revenue Next 2Y7.88%
Revenue Next 3Y7.5%
Revenue Next 5Y41.4%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
APYX Yearly Revenue VS EstimatesAPYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
APYX Yearly EPS VS EstimatesAPYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • APYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year APYX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APYX Price Earnings VS Forward Price EarningsAPYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APYX Per share dataAPYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • APYX's earnings are expected to grow with 14.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.18%
EPS Next 3Y14.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for APYX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APYX MEDICAL CORP

NASDAQ:APYX (2/25/2026, 8:00:01 PM)

3.42

-0.12 (-3.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners37.8%
Inst Owner Change20.23%
Ins Owners13.42%
Ins Owner Change0%
Market Cap140.25M
Revenue(TTM)47.90M
Net Income(TTM)-14.54M
Analysts80
Price Target5.87 (71.64%)
Short Float %0.37%
Short Ratio1.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.82%
Min EPS beat(2)5.46%
Max EPS beat(2)52.18%
EPS beat(4)4
Avg EPS beat(4)25.6%
Min EPS beat(4)5.46%
Max EPS beat(4)52.18%
EPS beat(8)6
Avg EPS beat(8)9.91%
EPS beat(12)7
Avg EPS beat(12)1.81%
EPS beat(16)9
Avg EPS beat(16)3.5%
Revenue beat(2)1
Avg Revenue beat(2)0.25%
Min Revenue beat(2)-4.69%
Max Revenue beat(2)5.19%
Revenue beat(4)2
Avg Revenue beat(4)0.78%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)5.19%
Revenue beat(8)4
Avg Revenue beat(8)0.71%
Revenue beat(12)5
Avg Revenue beat(12)-1.66%
Revenue beat(16)7
Avg Revenue beat(16)-1.7%
PT rev (1m)0%
PT rev (3m)1.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.71%
EPS NY rev (1m)0%
EPS NY rev (3m)14.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.93
P/FCF N/A
P/OCF N/A
P/B 23.98
P/tB 23.98
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS1.17
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.35%
ROE -248.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.65%
FCFM N/A
ROA(3y)-34.86%
ROA(5y)-28.54%
ROE(3y)-98.96%
ROE(5y)-68.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.12%
GM growth 5Y-2.02%
F-Score4
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 5.92
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 188.19%
Cap/Sales 2.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.44
Quick Ratio 3.61
Altman-Z 0.63
F-Score4
WACC11.02%
ROIC/WACCN/A
Cap/Depr(3y)103.68%
Cap/Depr(5y)91.24%
Cap/Sales(3y)1.6%
Cap/Sales(5y)1.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.29%
EPS Next Y52.43%
EPS Next 2Y20.18%
EPS Next 3Y14.41%
EPS Next 5Y18.24%
Revenue 1Y (TTM)-1.32%
Revenue growth 3Y-0.29%
Revenue growth 5Y11.24%
Sales Q2Q%12.1%
Revenue Next Year9.08%
Revenue Next 2Y7.88%
Revenue Next 3Y7.5%
Revenue Next 5Y41.4%
EBIT growth 1Y55.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.62%
EBIT Next 3Y20.48%
EBIT Next 5Y28.09%
FCF growth 1Y-16.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.07%
OCF growth 3YN/A
OCF growth 5YN/A

APYX MEDICAL CORP / APYX FAQ

Can you provide the ChartMill fundamental rating for APYX MEDICAL CORP?

ChartMill assigns a fundamental rating of 2 / 10 to APYX.


What is the valuation status for APYX stock?

ChartMill assigns a valuation rating of 0 / 10 to APYX MEDICAL CORP (APYX). This can be considered as Overvalued.


What is the profitability of APYX stock?

APYX MEDICAL CORP (APYX) has a profitability rating of 1 / 10.